Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Limited has scheduled its Annual General Meeting for shareholders on 22 May 2024, to be held in Sydney and accessible online. The company, known for developing diagnostic and therapeutic radiopharmaceuticals, has achieved significant regulatory milestones, including U.S. FDA and Australian TGA approvals for its lead imaging product, Illuccix®, and marketing authorization for SENSEI®, its surgical gamma probe.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
